AlloSeq cfDNA

Solid-organ Transplant Surveillance

AlloSeq cfDNA is an innovative NGS  solution that provides a risk assessment of allograft rejection by measuring dd-cfDNA.  Cell-free DNA is a clinically validated biomarker to measure the small amount of dd-cfDNA from plasma. AlloSeq cfDNA analyses transplant specific SNPs across the genome without prior genotyping.

To Request a Demo

Click Here

AlloSeq cfDNA

  • Targets 202 bi-allelic SNPs across 22 autosomes
  • Test up to 24 samples/run
  • Validated on Illumina MiniSeq and MiSeq
  • No prior genotyping required
  • Analytically validated by multi-centric study
  • From cfDNA sample to reported result < 24 hrs with < 1.5 hrs hands-on time
  • Allows reporting dd-cfDNA as fraction
  • Ability to calculate absolute copies
  • Ability to monitor more than one donor cfDNA contributor

For Full Details Visit

CareDx.com

Ordering Details

Share by: